ライフサイエンスコーパス: serotonin reuptake inhibitor

1 ocking properties of fluoxetine, a selective serotonin reuptake inhibitor.

2 lack of remission with an initial selective serotonin reuptake inhibitor.

3 mpus following administration of a selective serotonin reuptake inhibitor.

4 itor, the other from paroxetine, a selective serotonin-reuptake inhibitor.

5 Depressive patients medicated with Selective Serotonin Reuptake Inhibitors.

6 tracyclic antidepressants and norepinephrine-serotonin reuptake inhibitors.

7 itivity, and response to long-term selective serotonin reuptake inhibitors.

8 in patients that do not respond to selective serotonin reuptake inhibitors.

9 he absence of prenatal exposure to selective serotonin reuptake inhibitors.

10 ly active medications such as tricyclics and serotonin reuptake inhibitors.

11 tive to SERT inhibitors, including selective serotonin reuptake inhibitors.

12 ared with TCAs and strong compared with weak serotonin reuptake inhibitors.

13 disorder, GAD, or use of benzodiazepines or serotonin reuptake inhibitors.

14 a, often respond to treatment with selective serotonin reuptake inhibitors.

15 ame FDA "black box" warning as the selective serotonin reuptake inhibitors.

16 ars to lack drug interactions with selective serotonin reuptake inhibitors.

17 ting the antidepressant actions of selective serotonin reuptake inhibitors.

18 In contrast, the use of selective serotonin reuptake inhibitors (aHR for MOF, 1.43; 95% CI

19 Clinical trial data support selective serotonin reuptake inhibitors and amantadine to assist m

20 Regarding safety, serotonin reuptake inhibitors and bupropion may have low

21 inhibitors, patients taking higher doses of serotonin reuptake inhibitors and who had a longer durat

22 cological treatments, particularly selective serotonin-reuptake inhibitors and serotonin-noradrenalin

23 iazepines (-0.96, -1.56 to -0.36), selective serotonin-reuptake inhibitors and serotonin-norepinephri

24 to empirical treatments for the disorder-ie, serotonin-reuptake inhibitors and various forms of cogni

25 lthy volunteers with citalopram (a selective serotonin reuptake inhibitor) and contrasted its effects

26 cts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norep

27 benzodiazapines, and withdrawal of selective serotonin-reuptake inhibitor) and received cyproheptadin

28 erational effects of sertraline, a selective serotonin reuptake inhibitor, and venlafaxine, a seroton

29 cluding tricyclic antidepressants, selective serotonin reuptake inhibitors, and norepinephrine reupta

30 as atypical antipsychotic agents, selective serotonin reuptake inhibitors, and selective serotonin-n

31 -related issues: suicide risk with selective serotonin reuptake inhibitors, and the safety of antidep

32 and that the neurogenic effects of selective serotonin reuptake inhibitor antidepressants can success

33 acute, treatment with tricyclic or selective serotonin reuptake inhibitor antidepressants.

34 Serotonin reuptake inhibitors appear efficacious, but th

35 Selective serotonin reuptake inhibitors are the most widely prescr

36 Selective serotonin reuptake inhibitors are widely prescribed for

37 Current treatments, such as selective serotonin reuptake inhibitors, are not ideal because onl

38 Compared with selective serotonin reuptake inhibitors as a drug class, other cla

39 ce continues to support the use of selective serotonin reuptake inhibitors as first-line pharmacologi

40 vidence supporting the efficacy of selective serotonin reuptake inhibitors, augmentation strategies a

41 hift in prescribing toward the non-selective serotonin reuptake inhibitor bupropion hydrochloride, ev

42 ASD associated with treatment with selective serotonin reuptake inhibitors by the mother during the y

43 year risk of MOF by 36% for use of selective serotonin reuptake inhibitors, by 63% for use of mood st

44 of hip fracture by 57% for use of selective serotonin reuptake inhibitors, by 98% for use of mood st

45 double-blind design to receive the selective serotonin reuptake inhibitor citalopram (20 mg) or place

46 We observed dissociable effects of the serotonin reuptake inhibitor citalopram and the dopamine

47 We therefore examined whether the selective serotonin reuptake inhibitor citalopram improves respons

48 The selective serotonin reuptake inhibitor citalopram reduced mortalit

49 A subset of animals received selective serotonin reuptake inhibitor citalopram starting 7 days

50 agonists (BI-11A7 and BI-2A7); the selective serotonin reuptake inhibitor citalopram was used as a po

51 ctivity of a subactive dose of the selective serotonin reuptake inhibitor citalopram.

52 hallenge with an acute dose of the selective serotonin reuptake inhibitor, citalopram, revealed a gen

53 in response to challenge with the selective serotonin reuptake inhibitor, citalopram.

54 cerebral metabolic response to the selective serotonin reuptake inhibitor, citalopram.

55 pre-HAART or HAART era (P = .23), and use of serotonin reuptake inhibitors did not alter the risk of

56 ether fluoxetine, the prototypical selective serotonin reuptake inhibitor, differentially modulates n

57 entin and pregabalin) and the norepinephrine/serotonin reuptake inhibitors (duloxetine and milnacipra

58 benzodiazepine, and 293 were treated with a serotonin reuptake inhibitor during pregnancy.

59 c deletion or brief treatment with selective serotonin reuptake inhibitors during development, have a

60 Use of selective serotonin reuptake inhibitors during the second and/or t

61 of exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, during adolescence on beha

62 e of antidepressants, specifically selective serotonin reuptake inhibitors, during the second and/or

63 get for antidepressants, including selective serotonin reuptake inhibitors (e.g. (S)-citalopram) and

64 without its deleterious effect on selective serotonin reuptake inhibitor efficacy.

65 8 weeks with either placebo or the selective serotonin reuptake inhibitor escitalopram.

66 with subsequent remission with the selective serotonin reuptake inhibitor escitalopram; this is consi

67 8 weeks after randomization to the selective serotonin reuptake inhibitors escitalopram and sertralin

68 ponded significantly better to the selective serotonin reuptake inhibitors escitalopram and sertralin

69 oma were randomized to either placebo or the serotonin reuptake inhibitor, escitalopram (ESC) 10-20 m

70 ether a 3-week administration of a selective serotonin reuptake inhibitor, expected to increase brain

71 the antidepressant efficacy of the selective-serotonin reuptake inhibitor fluoxetine (FLX) in a chron

72 In contrast, the serotonin reuptake inhibitor fluoxetine (FLX) reduced im

73 The serotonin reuptake inhibitor fluoxetine selectively supp

74 Treatment with the selective serotonin reuptake inhibitor fluoxetine suppressed BMP s

75 Postnatal treatment with the selective serotonin reuptake inhibitor fluoxetine, evokes anxiety

76 reversed by administration of the selective serotonin reuptake inhibitor fluoxetine.

77 ehaviors, and is alleviated by the selective serotonin reuptake inhibitor fluoxetine.

78 ort and binding of cocaine and the selective serotonin reuptake inhibitors fluoxetine and escitalopra

79 droxyphenylserine at 5 mg/kg) or a selective serotonin reuptake inhibitor (fluoxetine at 20 mg/kg) at

80 ally exposed to acute doses of the selective serotonin reuptake inhibitor, fluoxetine (5 or 25 mg/L),

81 ssical therapeutics, including the selective serotonin reuptake inhibitor, fluoxetine.

82 sterone blocked the ability of the selective serotonin reuptake inhibitor, fluvoxamine, to inhibit se

83 gether with the demonstrated efficacy of the serotonin reuptake inhibitors for childhood-onset obsess

84 egan demonstrating the efficacy of selective serotonin reuptake inhibitors for these conditions in th

85 -current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment of depres

86 -CCKR-2 tg mice with fluoxetine, a selective serotonin reuptake inhibitor, for a period of 4 wk signi

87 Fluoxetine, a selective serotonin reuptake inhibitor, has been found recently to

88 Fluoxetine, a selective serotonin reuptake inhibitor, has been reported to reduc

89 Fluoxetine (FLX), a selective serotonin reuptake inhibitor, has similar effects in cul

90 h cognitive behavioral therapy and selective serotonin-reuptake inhibitors have shown efficacy in tre

91 cortex are powerfully modulated by selective serotonin reuptake inhibitors, however, direct measureme

92 uld be relevant to some actions of selective serotonin reuptake inhibitors in humans.

93 er a 12-week treatment course with selective serotonin reuptake inhibitors in late-life depression.

94 f cognitive behavioral therapy and selective serotonin reuptake inhibitors in the treatment of pediat

95 The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unkn

96 Long-term efficacy and safety of selective serotonin reuptake inhibitors in these patients are unkn

97 of children exposed prenatally to selective serotonin reuptake inhibitors in this population was low

98 We identified citalopram, a selective serotonin reuptake inhibitor, in a small molecule screen

99 iological effects of fluoxetine, a selective serotonin reuptake inhibitor, in filter and deposit feed

100 Maternal treatment with a serotonin reuptake inhibitor is also associated with hyp

101 aroxetine (Paxil), the most potent selective serotonin reuptake inhibitor known.

102 Treatment with serotonin reuptake inhibitors may be most beneficial in

103 Although treatment with serotonin reuptake inhibitors may lead to a small increa

104 Selective serotonin reuptake inhibitors may provide benefit by red

105 substances, such as increasingly prescribed serotonin reuptake inhibitors, may produce an independen

106 rols); unmedicated-MDD; and MDD treated with serotonin reuptake inhibitors (MDD*SSRI) or tricyclics (

107 treated, n = 12), MDD treated with selective serotonin reuptake inhibitors (MDD*SSRI, n = 6) or tricy

108 e-enhanced behavior therapy) and medication (serotonin reuptake inhibitors, N-acetylcysteine, or nalt

109 second-generation antidepressants (selective serotonin reuptake inhibitors, nefazodone, venlafaxine,

110 Use of selective serotonin reuptake inhibitors, nonbenzodiazepine hypnoti

111 ession classified as responsive to selective serotonin reuptake inhibitors (odds ratio=1.55, 95% CI=1

112 s into the effects of OLZ, but not selective serotonin reuptake inhibitors, on core features of AN.

113 antidepressant medication therapy (selective serotonin reuptake inhibitor or serotonin and norepineph

114 ndomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, with or wit

115 0-week open-label treatment with a selective serotonin reuptake inhibitor or, in some cases, another

116 setron) either in combination with selective serotonin reuptake inhibitors or as monotherapy in the t

117 treatment of depression by use of selective serotonin reuptake inhibitors or psychological approache

118 lly untreated maternal depression, selective serotonin reuptake inhibitors or serotonin and norepinep

119 wnregulated by the acute action of selective serotonin reuptake inhibitors or serotonin at the site o

120 preterm birth are high for women who used a serotonin reuptake inhibitor (OR, 1.55 [95% CI, 1.02-2.3

121 rval [CI] = 1.10-15.14) and use of selective serotonin reuptake inhibitors (OR = 2.66; 95% CI = 1.01-

122 edicted response to antidepressants overall, serotonin reuptake inhibitors, or noradrenaline reuptake

123 ncludes tricyclic antidepressants, selective serotonin reuptake inhibitors, or psychosocial intervent

124 Recently we identified the serotonin reuptake inhibitor paroxetine as an inhibitor

125 s applied to the synthesis of the commercial serotonin reuptake inhibitor (-)-paroxetine.

126 The selective serotonin reuptake inhibitor, paroxetine, was previously

127 Compared with patients who were not taking serotonin reuptake inhibitors, patients taking higher do

128 primary care settings, the effectiveness of serotonin reuptake inhibitor prescription by pediatric p

129 Although current antidepressants, such as serotonin-reuptake inhibitors, produce subtle changes th

130 muli, and possible off-target effects of the serotonin reuptake inhibitor Prozac.

131 reatment of Hoxb8 mutants with fluoxetine, a serotonin reuptake inhibitor, reduces excessive grooming

132 Fluoxetine is the only selective serotonin reuptake inhibitor registered for the treatmen

133 behavioral therapy with or without selective serotonin reuptake inhibitors remains a preferred initia

134 hether this model is responsive to selective serotonin reuptake inhibitors remains unspecified.

135 in women with MDD or anxiety, with selective serotonin reuptake inhibitors reported as the most commo

136 f classic antidepressants, such as selective serotonin reuptake inhibitors, require a month or longer

137 e itch triggered by serotonin or a selective serotonin reuptake inhibitor required both HTR7 and TRPA

138 nt exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, results in changes to the

139 case report suggested benefit from selective serotonin reuptake inhibitor/serotonin-norepinephrine re

140 excess morbidity in critically ill selective serotonin reuptake inhibitor/serotonin-norepinephrine re

141 as generally unclear if outpatient selective serotonin reuptake inhibitor/serotonin-norepinephrine re

142 Selective serotonin reuptake inhibitor/serotonin-norepinephrine re

143 dies of ICU patients with recorded selective serotonin reuptake inhibitor/serotonin-norepinephrine re

144 exposed and control groups; use of selective serotonin reuptake inhibitor/serotonin-norepinephrine re

145 help clinicians decide when to use selective serotonin reuptake inhibitor/serotonin-norepinephrine re

146 antidepressant treatment with the selective serotonin reuptake inhibitor sertraline hydrochloride.

147 Participants were 73 serotonin reuptake inhibitor (SRI) nonresponders with ma

148 ne unmedicated (n = 12) and one treated with serotonin reuptake inhibitors (SRI; n = 13).

149 Notably, serotonin reuptake inhibitors (SRIs) are antidepressant

150 Although serotonin reuptake inhibitors (SRIs) are approved for th

151 Serotonin reuptake inhibitors (SRIs) are efficacious tre

152 Serotonin reuptake inhibitors (SRIs) are the only medica

153 der (OCD) indicates that partial response to serotonin reuptake inhibitors (SRIs) is the norm and tha

154 Serotonin reuptake inhibitors (SRIs), the first-line pha

155 iety disorders, which are often treated with serotonin reuptake inhibitors (SRIs).

156 rder (OCD) exhibit an inadequate response to serotonin reuptake inhibitors (SRIs).

157 Chronic selective serotonin reuptake inhibitor (SSRI) administration to ro

158 ndicated that the combination of a selective serotonin reuptake inhibitor (SSRI) and a statin may hav

159 ollowing administration of several selective serotonin reuptake inhibitor (SSRI) antidepressant drugs

160 splays distinct sensitivity to the selective serotonin reuptake inhibitor (SSRI) antidepressant fluox

161 The association between selective serotonin reuptake inhibitor (SSRI) antidepressant use d

162 ychotic medications; fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant; and

163 sant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepressants, all

164 , either untreated or treated with selective serotonin reuptake inhibitor (SSRI) antidepressants, and

165 Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has

166 ian subjects were administered the selective serotonin reuptake inhibitor (SSRI) citalopram (10 mg) i

167 Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram decreases

168 his study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram downregul

169 (TCA) desipramine (10 mg/kg), the selective serotonin reuptake inhibitor (SSRI) fluoxetine (10 mg/kg

170 The selective serotonin reuptake inhibitor (SSRI) fluoxetine (FLX), th

171 e early anxiogenic response to the selective serotonin reuptake inhibitor (SSRI) fluoxetine and had i

172 onstrated that chronic administration of the serotonin reuptake inhibitor (SSRI) fluoxetine augments

173 hat 6 weeks' administration of the selective serotonin reuptake inhibitor (SSRI) fluoxetine would amp

174 s and advantages compared with the selective serotonin reuptake inhibitor (SSRI) fluoxetine.

175 aled that chronic treatment with a selective serotonin reuptake inhibitor (SSRI) impairs the acquisit

176 A subset of patients started on a selective serotonin reuptake inhibitor (SSRI) initially experience

177 cally supported psychotherapy with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy as t

178 or to beginning treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline or cognit

179 randomized controlled trial of the selective serotonin reuptake inhibitor (SSRI) sertraline.

180 (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy.

181 was synthesized by linking a novel selective serotonin reuptake inhibitor (SSRI) to a PDE4 inhibitor.

182 the relationship between prenatal selective serotonin reuptake inhibitor (SSRI) treatment and pregna

183 Although selective serotonin reuptake inhibitor (SSRI) treatment is known t

184 obust therapeutic response to evidence-based serotonin reuptake inhibitor (SSRI) treatment.

185 Selective serotonin reuptake inhibitor (SSRI) use during pregnancy

186 ERT) were synthesized based on the selective serotonin reuptake inhibitor (SSRI), (S)-citalopram (1).

187 fects of duloxetine hydrochloride, selective serotonin reuptake inhibitor (SSRI), and covariates on t

188 Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), blocks GCS-induced

189 In the presence of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), concentrations of 5

190 re not rescued with the prototypic selective serotonin reuptake inhibitor (SSRI), fluoxetine.

191 ted the effects of escitalopram, a selective serotonin reuptake inhibitor (SSRI), on brain activation

192 es demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), provided the most s

193 dolescents (ages 12-18 years) with selective serotonin reuptake inhibitor (SSRI)-resistant depression

194 nt with citalopram, a prototypical selective serotonin reuptake inhibitor (SSRI).

195 an initial treatment trial with a selective serotonin reuptake inhibitor (SSRI).

196 after 8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI).

197 after ~8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI).

198 we show that when the effects of a selective serotonin reuptake inhibitor (SSRI, citalopram) are stud

199 Selective serotonin reuptake inhibitors (SSRI's) enhance neural pl

200 Selective serotonin reuptake inhibitors (SSRI) are aimed at increa

201 Selective serotonin reuptake inhibitors (SSRI) are known to increa

202 rated that acute administration of selective serotonin reuptake inhibitors (SSRI) can affect P-gp fun

203 studied the effect of fluoxetine (a specific serotonin reuptake inhibitor--SSRI) on active avoidance

204 sms explaining hormetic effects of selective serotonin reuptake inhibitors (SSRIs) and 4-nonylphenol

205 strongest evidence supports use of selective serotonin reuptake inhibitors (SSRIs) and cognitive-beha

206 ors, both of which are reversed by selective serotonin reuptake inhibitors (SSRIs) and the tricyclic

207 Selective serotonin reuptake inhibitors (SSRIs) are a first-line t

208 Selective serotonin reuptake inhibitors (SSRIs) are antidepressant

209 Compared with placebo, selective serotonin reuptake inhibitors (SSRIs) are associated wit

210 Selective serotonin reuptake inhibitors (SSRIs) are commonly presc

211 Selective serotonin reuptake inhibitors (SSRIs) are commonly presc

212 Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly used

213 Selective serotonin reuptake inhibitors (SSRIs) are efficacious fo

214 Selective serotonin reuptake inhibitors (SSRIs) are frequently pre

215 Selective serotonin reuptake inhibitors (SSRIs) are often recommen

216 Selective serotonin reuptake inhibitors (SSRIs) are the most commo

217 Selective serotonin reuptake inhibitors (SSRIs) are the primary ph

218 Although selective serotonin reuptake inhibitors (SSRIs) are widely prescri

219 Selective serotonin reuptake inhibitors (SSRIs) are widely used an

220 Selective serotonin reuptake inhibitors (SSRIs) are widely used an

221 Selective serotonin reuptake inhibitors (SSRIs) are widely used an

222 Are selective serotonin reuptake inhibitors (SSRIs) associated with be

223 Selective serotonin reuptake inhibitors (SSRIs) display a delayed

224 an association between the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy a

225 Use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy h

226 It is unknown whether exposure to selective serotonin reuptake inhibitors (SSRIs) during pregnancy i

227 ongoing controversy as to whether selective serotonin reuptake inhibitors (SSRIs) exhibit the same a

228 ality in pediatric patients taking selective serotonin reuptake inhibitors (SSRIs) for depression.

229 Use of selective serotonin reuptake inhibitors (SSRIs) has been associate

230 Chronic treatments with selective serotonin reuptake inhibitors (SSRIs) have been shown to

231 In both rats and men, selective serotonin reuptake inhibitors (SSRIs) impair erection, e

232 The safety and efficacy of selective serotonin reuptake inhibitors (SSRIs) in adolescents is

233 dulation of synaptic plasticity by selective serotonin reuptake inhibitors (SSRIs) in hippocampal bra

234 ted that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major depressiv

235 blockers potentiate the effects of selective serotonin reuptake inhibitors (SSRIs) in some treatment-

236 gated whether in utero exposure to selective serotonin reuptake inhibitors (SSRIs) increases the risk

237 ating serotonin (5-HT) levels with selective serotonin reuptake inhibitors (SSRIs) is the most widely

238 Selective serotonin reuptake inhibitors (SSRIs) may increase the r

239 g animals with MAO-A inhibitors or selective serotonin reuptake inhibitors (SSRIs) normalized anxiety

240 sess the effects of treatment with selective serotonin reuptake inhibitors (SSRIs) on the risks of ge

241 SM) advised against treatment with selective serotonin reuptake inhibitors (SSRIs) other than fluoxet

242 Selective serotonin reuptake inhibitors (SSRIs) represent a class

243 Compared with pill placebo, selective serotonin reuptake inhibitors (SSRIs) significantly redu

244 D, and clinical data indicate that selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine

245 ion accounting for unsatisfactory effects of serotonin reuptake inhibitors (SSRIs) such as insufficie

246 utomer, escitalopram (S-(+)-1) are selective serotonin reuptake inhibitors (SSRIs) that are used clin

247 m concomitant use of nsNSAIDs with selective serotonin reuptake inhibitors (SSRIs) was 1.6, whereas t

248 udies linking in utero exposure to selective serotonin reuptake inhibitors (SSRIs) with persistent pu

249 orepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depr

250 respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), and this is assoc

251 rinatal exposure to drugs, such as selective serotonin reuptake inhibitors (SSRIs), impacts cortical

252 Selective serotonin reuptake inhibitors (SSRIs), in addition to th

253 compared for patients who received selective serotonin reuptake inhibitors (SSRIs), new-generation no

254 ge of therapeutic agents including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradre

255 he relative efficacy and safety of selective serotonin reuptake inhibitors (SSRIs), serotonin-norepin

256 Selective serotonin reuptake inhibitors (SSRIs), such as citalopra

257 ich dampen limbic irritability, or selective serotonin reuptake inhibitors (SSRIs), which may enhance

258 of fluoxetine and paroxetine, two selective serotonin reuptake inhibitors (SSRIs), with the human (h

259 the introduction and diffusion of selective serotonin reuptake inhibitors (SSRIs).

260 sive Disorder who are treated with Selective Serotonin Reuptake Inhibitors (SSRIs).

261 havioral and cellular responses to selective serotonin reuptake inhibitors (SSRIs).

262 nitive-behavioral therapy (CBT) or selective serotonin reuptake inhibitors (SSRIs).

263 partial response or no response to selective serotonin reuptake inhibitors (SSRIs).

264 eclampsia among women treated with selective serotonin reuptake inhibitors (SSRIs).

265 emical and behavioral responses to selective serotonin reuptake inhibitors (SSRIs).

266 itro and functionally responded to selective serotonin reuptake inhibitors (SSRIs).

267 ved in patients chronically taking selective serotonin reuptake inhibitors (SSRIs).

268 aviour following acute exposure to selective serotonin reuptake inhibitors (SSRIs).

269 i-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs).

270 ation and is commonly treated with selective serotonin reuptake inhibitors (SSRIs; e.g., Prozac).

271 Whether the use of selective serotonin-reuptake inhibitors (SSRIs) and other antidepr

272 eductase inhibitors (statins), and selective serotonin-reuptake inhibitors (SSRIs) and serotonin-nore

273 The use of selective serotonin-reuptake inhibitors (SSRIs) has been associate

274 efects after antenatal exposure to selective serotonin-reuptake inhibitors (SSRIs) remains controvers

275 nuates the therapeutic activity of selective serotonin-reuptake inhibitors (SSRIs), whereas their fun

276 Antidepressant use (selective serotonin reuptake inhibitors [SSRIs] or serotonin-norep

277 ine to comparators (venlafaxine or selective serotonin reuptake inhibitors [SSRIs], and individuals w

278 d declines in case finding and non-selective serotonin reuptake inhibitor substitute treatment were s

279 ith subchronic administration of a selective serotonin reuptake inhibitor, suggesting the predictive

280 The effectiveness of serotonin reuptake inhibitors, taken throughout the cycl

281 oral changes were rescued by acute selective serotonin reuptake inhibitor treatment, supporting the h

282 sed to assess cataract surgery and selective serotonin reuptake inhibitor treatment.

283 velops in patients with MDD during selective serotonin reuptake inhibitor treatment.

284 a, and an increased sensitivity to selective serotonin reuptake inhibitor treatment.

285 Acute SSRI (selective serotonin reuptake inhibitor) treatment has been shown t

286 iazepine hypnotics, beta-blockers, selective serotonin reuptake inhibitors, tricyclic antidepressants

287 to whether patients were receiving selective serotonin reuptake inhibitors, tricyclic antidepressants

288 ute odds ratios for differences in selective serotonin reuptake inhibitor use between cases and contr

289 Selective serotonin reuptake inhibitor use decreased in all cohort

290 and adolescents, the risk benefit ratio for serotonin reuptake inhibitor use in pediatric anxiety di

291 Selective serotonin reuptake inhibitor use of 1 or more years in p

292 Selective serotonin reuptake inhibitor use of 1 or more years was

293 Maternal serotonin reuptake inhibitor use was associated with hyp

294 ion was shortened by 3.6 days; with maternal serotonin reuptake inhibitor use, gestation was shortene

295 York Heart Association class, and selective serotonin reuptake inhibitor use.

296 of 6024 residents, 1024 (17%) were selective serotonin reuptake inhibitor users compared to 788 (13%)

297 For SERT analysis, patients on selective serotonin reuptake inhibitor were excluded (n = 48 remai

298 s who were partial responders to a selective serotonin reuptake inhibitor were randomized to receive

299 This study compared a serotonin reuptake inhibitor with a noradrenergic/dopami

300 used to examine the effect of treatment with serotonin reuptake inhibitors, with or without antipsych